CD BioGlyco has developed a first-class Site-Specific Antibody Conjugation platform. We provide site-specific antibody conjugation services with biotin for global clients through glycan-mediated conjugation methods.
Due to their high affinity and ability to selectively bind to specific target molecules, antibodies are considered effective tools in many medical and biological applications. Scientists have long coupled antibodies to a variety of reagents to confer other desirable but unnatural functions on antibodies. For example, fluorescent or radioactive labels are added to antibodies for use in enzyme-linked immunosorbent assays (ELISA). Antibodies are coupled with small-molecule drugs to create new drugs, known as antibody-drug conjugates (ADCs), to improve drug efficacy. Conjugation technology is the key to developing high-quality antibody conjugates. The traditional approach is to attach the conjugate to the antibody in a nonspecific manner. This non-selective conjugation method not only affects the natural structure of the antibody but may also cover the active site of the antibody and reduce its biological activity. To solve the drawbacks of traditional conjugation techniques, a new site-specific conjugation technique has been reported in recent years.
Fig.1 Antibody labeling. (von Witting, et al., 2021)
Site-specific conjugation is the site-specific attachment of chemical tags to specific sites on an antibody, resulting in a homogeneous and well-defined conjugate without compromising its biological activity. Standard and practical methods of site-specific bioconjugation of natural antibodies include chemo-enzymatic techniques and chemical conjugation. Here, we describe the site-specific conjugation of the conserved Fc region of antibodies by chemo-enzymatic methods. Chemo-enzymatic methods are usually site-specific and performed under mild conditions. It is achieved by modification of the conserved glutamine residues mediated by transglutaminase (TGase) or glycan remodeling of the conserved Asp N-glycans.
Since antibody conjugation plays an important role in many medical and biological applications. At CD BioGlyco, we have developed site-specific antibody conjugation technology to produce homogeneous and well-defined conjugates. All IgG-type antibodies have only one glycan at a conserved site of the Fc region. Therefore, we attach biotin to specific positions of the antibody (from humans, mice, rats, goats, sheep, monkeys, rabbits, cows, and horses) by a glycan-mediated site-specific conjugation technique. Our specific method is as follows:
1) Trim the antibody's native glycan by β-galactosidase or hydrolyze the Fc glycan to the innermost N-acetylglucosamine (GlcNAc) by endoglycosidase.
2) Install a functionalized unnatural sugar containing a handle to activate the antibody.
3) Under specific conditions, biotin is conjugated to an activated antibody containing a handle.
Fig.2 Process of site-specific antibody conjugation with biotin. (CD BioGlyco)
CD BioGlyco specializes in Antibody Glycoengineering and has been recognized by scientists from many countries. We are willing to share our knowledge and experience in this field. If you are interested in our site-specific antibody conjugation with biotin, please contact us for more details.
References:
